U.K. drugmaker McCallum gets FDA warning over data, testing issues

U.K. drugmaker McCallum gets FDA warning over data, testing issues. (FDA)

McCallum, a U.K.-based drugmaker, was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

In the letter posted on the regulatory agency’s website, the FDA took McCallum to task when the company said in response to a July 2017 inspection that it was too small an enterprise and didn’t have the resources for a quality unit.

“Regardless of the size of your company, as a drug manufacturer, you must have a quality unit that is responsible for and authorized to perform certain operations,” the FDA wrote.

McCallum, an over-the-counter manufacturing operation, was found to lack testing procedures, specifications and analytical data to support the release of its products. The company also didn’t have adequate written procedures for production and process control in place, as well as failing to prepare batch production and control records.

The agency recommended the company hire a CGMP consultant to fix the issues.

Suggested Articles

A new bipartisan Senate bill would seek a full accounting of the U.S. supply of medicines produced by foreign drug manufacturers.

Fufjilm taps Dr. Reddy's and GRA to make flu drug Avigan for potential COVID-19 treament even as clinical progress lags behind schedule.

Novartis will open a new U.S. manufacturing plant in 2023 to meet growing demand for drugs that use radioactive particles to target tumors.